Protein-Binding Properties of Two Antitumour Ru(III) Complexes
Author Information
Author(s): F. Kratz, B.K. Keppler, L. Messori, C. Smith, E.N. Baker
Primary Institution: University of Heidelberg
Hypothesis
The study investigates the interaction of two ruthenium(III) complexes with human serum apotransferrin to prepare adducts selective for cancer cells.
Conclusion
The less toxic complex binds rapidly to apotransferrin, suggesting it can effectively deliver drugs to tumor tissues.
Supporting Evidence
- The binding of the less toxic complex occurs within minutes, while the more toxic complex takes hours.
- Binding occurs at histidine residues, confirming previous studies.
- Apotransferrin-bound complex shows higher antitumour activity against colon cancer cells.
Takeaway
This study looks at how two special metal compounds can stick to proteins in our blood, which might help deliver cancer medicine right to the tumor.
Methodology
The study used spectroscopic and chromatographic techniques to investigate the binding of ruthenium(III) complexes to apotransferrin.
Limitations
The results are preliminary and full crystallographic refinements have not yet been carried out.
Want to read the original?
Access the complete publication on the publisher's website